Gilead Sciences | GILD - Loan Capital

Stock Price
141.11
Daily Change
-0.18 -0.13%
Monthly
-6.80%
Yearly
33.29%
Q1 Forecast
140.61

Gilead Sciences reported $22.14B in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 285.82M 639K Sep/2024
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Coherus Biosciences USD 51.08M 496K Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Glaxosmithkline GBP 19.82B 203.13M Dec/2025
Incyte USD 30.2M 5.17M Dec/2025
J&J USD 39.44B 30M Dec/2025
Merck USD 39.97B 6B Sep/2025
Moderna USD 610M 584M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 29.59B 5.35B Dec/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 15.72B 2.45B Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025